lapatinib has been researched along with dactolisib in 11 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (dactolisib) | Trials (dactolisib) | Recent Studies (post-2010) (dactolisib) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 444 | 14 | 405 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Durden, DL; Garlich, JR; Morales, GA; Newblom, J; Peng, X; Su, J; Weber, K | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Baselga, J; Beijersbergen, RL; Bernards, R; Eichhorn, PJ; Gili, M; Guzman, M; Nijkamp, W; Scaltriti, M; Seoane, J; Serra, V; Valero, V | 1 |
| Ahuja, D; Amin, DN; Blair, JA; Hann, B; Koch, KM; McMahon, M; Moasser, MM; Sergina, N; Shokat, KM; Wang, D | 1 |
| Axelrod, MJ; Conaway, MR; Gioeli, DG; Gordon, V; Jameson, MJ; Leimgruber, SS; Mendez, RE; Sharlow, ER; Weber, MJ | 1 |
| Brady, SW; Chang, CC; Chang, J; Ellis, K; Esteva, FJ; Landis, MD; Muller, WJ; Priya, P; Sahin, O; Wang, H; Wang, Q; Wong, ST; Yu, D; Zhang, Q; Zhu, R | 1 |
| Airhart, S; Bult, C; Davis, RR; de Vere White, RW; Gandara, DR; Ghosh, PM; Gill, P; Keck, J; Lin, TY; Liu, E; Pan, CX; Tepper, CG; Zhang, H | 1 |
| Amin, DN; Gulizia, N; Moasser, MM; Ruiz-Saenz, A | 1 |
| Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU | 1 |
1 trial(s) available for lapatinib and dactolisib
| Article | Year |
|---|---|
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Topics: Animals; Female; Heterografts; Humans; Imidazoles; Lapatinib; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
10 other study(ies) available for lapatinib and dactolisib
| Article | Year |
|---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
Topics: Antineoplastic Agents; Cell Proliferation; Chromones; Enzyme Inhibitors; Humans; MCF-7 Cells; Morpholines; Neoplastic Stem Cells; Phosphoinositide-3 Kinase Inhibitors; Structure-Activity Relationship; Thiophenes | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carrier Proteins; Cell Line, Tumor; Drug Resistance; Female; Humans; Imidazoles; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2008 |
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lapatinib; Mice; Mitogen-Activated Protein Kinases; Neoplasms; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2010 |
p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.
Topics: Apoptosis; Cell Line, Tumor; ErbB Receptors; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Lapatinib; Mice; Mice, Transgenic; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Tumor Cells, Cultured | 2014 |
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Indoles; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2017 |